Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385687089> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4385687089 endingPage "165.13" @default.
- W4385687089 startingPage "165.13" @default.
- W4385687089 abstract "Abstract Study objective: The activity of linsitinib, a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), was assessed in a mouse model of Graves’ orbitopathy (GO). GO is the most common extra-thyroidal manifestation of Graves’ disease (GD), which is caused by autoantibodies against the thyroid stimulating hormone receptor (TSHR). Methods: GD was induced in mice by immunization with a human TSHR A-subunit encoding plasmid. Linsitinib was administered orally for four weeks either in parallel to or after disease induction. Endocrine orbitopathy and inflammation were determined by histology and MRI. Results: Immunization with the TSHR A-subunit induced hyperthyroidism, as well as CD3+ T-cell infiltration and macrophage infiltration into orbital muscle/adipose tissue. Linsitinib reduced these effects by up to 80% whether given prophylactically or after disease induction. In addition, linsitinib reduced the formation of brown adipose tissue in the orbit and displayed an additional effect on the immune system. An MRI using F19 imaging confirmed marked orbital inflammation, significant muscle edema and formation of brown fat in experimental GO, events that were abrogated upon application of linsitinib. Linsitinib’s pharmacologic effects were observed at a dose that did not impact the concentration of plasma glucose. Conclusion: Linsitinib improved GO-related endpoints in a TSHR autoantibody dependent mouse model of Graves’ disease. Both prophylactic and therapeutic intervention with linsitinib improved clinically relevant endpoints in the orbita and thyroid gland. Our results are consistent with the therapeutic hypothesis being evaluated in an ongoing Phase 2b clinical study (NCT05276063). This work was funded by Sling Therapeutics, Inc." @default.
- W4385687089 created "2023-08-10" @default.
- W4385687089 creator A5002073335 @default.
- W4385687089 creator A5013570904 @default.
- W4385687089 creator A5019495317 @default.
- W4385687089 creator A5023308750 @default.
- W4385687089 creator A5027255737 @default.
- W4385687089 creator A5034796082 @default.
- W4385687089 creator A5035298951 @default.
- W4385687089 creator A5036004952 @default.
- W4385687089 creator A5051406368 @default.
- W4385687089 creator A5053468059 @default.
- W4385687089 creator A5053809986 @default.
- W4385687089 creator A5073697965 @default.
- W4385687089 creator A5076786068 @default.
- W4385687089 creator A5082021491 @default.
- W4385687089 date "2023-05-01" @default.
- W4385687089 modified "2023-09-27" @default.
- W4385687089 title "Treatment with linsitinib, an IGF-1 receptor inhibitor, attenuates disease development and progression in an experimental model of Graves’ Orbitopathy" @default.
- W4385687089 doi "https://doi.org/10.4049/jimmunol.210.supp.165.13" @default.
- W4385687089 hasPublicationYear "2023" @default.
- W4385687089 type Work @default.
- W4385687089 citedByCount "0" @default.
- W4385687089 crossrefType "journal-article" @default.
- W4385687089 hasAuthorship W4385687089A5002073335 @default.
- W4385687089 hasAuthorship W4385687089A5013570904 @default.
- W4385687089 hasAuthorship W4385687089A5019495317 @default.
- W4385687089 hasAuthorship W4385687089A5023308750 @default.
- W4385687089 hasAuthorship W4385687089A5027255737 @default.
- W4385687089 hasAuthorship W4385687089A5034796082 @default.
- W4385687089 hasAuthorship W4385687089A5035298951 @default.
- W4385687089 hasAuthorship W4385687089A5036004952 @default.
- W4385687089 hasAuthorship W4385687089A5051406368 @default.
- W4385687089 hasAuthorship W4385687089A5053468059 @default.
- W4385687089 hasAuthorship W4385687089A5053809986 @default.
- W4385687089 hasAuthorship W4385687089A5073697965 @default.
- W4385687089 hasAuthorship W4385687089A5076786068 @default.
- W4385687089 hasAuthorship W4385687089A5082021491 @default.
- W4385687089 hasBestOaLocation W43856870891 @default.
- W4385687089 hasConcept C126322002 @default.
- W4385687089 hasConcept C134018914 @default.
- W4385687089 hasConcept C159654299 @default.
- W4385687089 hasConcept C163764329 @default.
- W4385687089 hasConcept C170493617 @default.
- W4385687089 hasConcept C171089720 @default.
- W4385687089 hasConcept C203014093 @default.
- W4385687089 hasConcept C2776652619 @default.
- W4385687089 hasConcept C2776685619 @default.
- W4385687089 hasConcept C2776914184 @default.
- W4385687089 hasConcept C2777608072 @default.
- W4385687089 hasConcept C526584372 @default.
- W4385687089 hasConcept C71924100 @default.
- W4385687089 hasConcept C8891405 @default.
- W4385687089 hasConceptScore W4385687089C126322002 @default.
- W4385687089 hasConceptScore W4385687089C134018914 @default.
- W4385687089 hasConceptScore W4385687089C159654299 @default.
- W4385687089 hasConceptScore W4385687089C163764329 @default.
- W4385687089 hasConceptScore W4385687089C170493617 @default.
- W4385687089 hasConceptScore W4385687089C171089720 @default.
- W4385687089 hasConceptScore W4385687089C203014093 @default.
- W4385687089 hasConceptScore W4385687089C2776652619 @default.
- W4385687089 hasConceptScore W4385687089C2776685619 @default.
- W4385687089 hasConceptScore W4385687089C2776914184 @default.
- W4385687089 hasConceptScore W4385687089C2777608072 @default.
- W4385687089 hasConceptScore W4385687089C526584372 @default.
- W4385687089 hasConceptScore W4385687089C71924100 @default.
- W4385687089 hasConceptScore W4385687089C8891405 @default.
- W4385687089 hasIssue "1_Supplement" @default.
- W4385687089 hasLocation W43856870891 @default.
- W4385687089 hasOpenAccess W4385687089 @default.
- W4385687089 hasPrimaryLocation W43856870891 @default.
- W4385687089 hasRelatedWork W1964688190 @default.
- W4385687089 hasRelatedWork W1978718098 @default.
- W4385687089 hasRelatedWork W1994889999 @default.
- W4385687089 hasRelatedWork W2017606817 @default.
- W4385687089 hasRelatedWork W2027098794 @default.
- W4385687089 hasRelatedWork W2049045125 @default.
- W4385687089 hasRelatedWork W2081564223 @default.
- W4385687089 hasRelatedWork W2103307877 @default.
- W4385687089 hasRelatedWork W2167541966 @default.
- W4385687089 hasRelatedWork W2748952813 @default.
- W4385687089 hasVolume "210" @default.
- W4385687089 isParatext "false" @default.
- W4385687089 isRetracted "false" @default.
- W4385687089 workType "article" @default.